Hypothesis-Generating Brief: Hyperbaric oxygen

Artifact

Living evidence brief from agent-v3-full-paper-live

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Reconcile the corpus with the stated geroscience/aging scope: either narrow the scope to 'HBOT across multiple clinical indications with a bounded geroscience subclaim,' or expand the bundle with sources that actually test HBOT for aging-relevant hard endpoints (telomere length, cognitive aging, mortality in older adults). The current bundle does not support the framing of an 'aging' evidence map.
2. Bring all author-year citations in the prose into the source bundle (Fang 2025, Pindovic 2026, Peng 2025, Alp 2026, Balasubramanian 2021, and any reference to Ioannidis 2005) or remove them, and add a per-source mapping that ties each cited claim to a specific bundle entry with a stable ID.
3. Fix the outcome-class accounting so that the sum of sources and claims across Contextual Adjacent Evidence, Safety and Comorbidity, Immune and Inflammation, and Deficiency Prevalence equals the 27 admitted sources and 699 claims reported in the abstract; resolve the duplicate Immune and Inflammation row.
4. Define 'cross-study disagreement' operationally (e.g., disagreement = any two sources in the same outcome class with opposing directional codes or non-overlapping CIs) and report the count under that definition so the 75-disagreement figure is auditable.
5. Rewrite the Tensions and Gaps section so that recommended next-step studies correspond to actual gaps in the mapped bundle (e.g., comparative effectiveness of HBOT vs. IVT for CRAO given Bakdalieh 2026; long-term neurological follow-up after CO poisoning given Xu 2026 and Fujita 2026's null pooled result) rather than the generic 'safety comorbidity, deficiency prevalence, contextual other' template.

Major issues

• The evidence map's central thesis (HBOT as a bounded geroscience case with mechanistic credibility but no hard-endpoint proof) is not directly tied to the actual source bundle: the 27 admitted sources predominantly cover HBOT for CO poisoning, diabetic foot ulcers, radiation enteritis, CRAO, burns, TBI, fibromyalgia, sleep, SCI, and dental microleakage — not aging/longevity. The 'aging' framing is sustained almost entirely by Balasubramanian 2021 and Doenyas-Barak 2026, with the remaining ~25 sources being off-domain for the stated geroscience scope.
• Several cited_as entries in the prose (Fang 2025, Pindovic 2026, Peng 2025, Alp 2026, Balasubramanian 2021, Ioannidis 2005) are not present in the source bundle. Only 27 sources are in the bundle, and key author-year claims made in the Limitations and Findings sections reference at least one source (Ioannidis 2005) that is entirely absent from the bundle.
• The Findings Map table reports aggregate counts (n=18; claims=436 for Contextual Adjacent Evidence; n=4; claims=110 for Safety) that are not reconcilable with the 27-source bundle. If 23/27 sources are 'adjacent clinical,' the table slices and directness numbers do not match the bundle composition and are not auditable.
• The Results Summary section lists 'Immune and Inflammation' twice with different n and claim counts (n=2; claims=36 and n=1; claims=2) without an obvious reason; the total of 27 sources is not reconstructable from the stated outcome-class breakdown, indicating either a counting error or that the breakdown is drawn from a different evidence pack than the bundle.
• The Tensions and Gaps section recommends running 'adequately powered human studies that test hyperbaric oxygen against prespecified endpoints in safety comorbidity, deficiency prevalence, contextual other' — but no source in the bundle addresses deficiency prevalence for HBOT, and the recommendation reflects a generic template rather than a gap specific to the mapped evidence.

Minor issues

• The abstract and Scope section repeat near-identical prose blocks; the Scope section adds no information beyond the abstract.
• Several findings subsections (e.g., Deficiency Prevalence Outcomes) contain no prose content and acknowledge that 'retained narrative paragraphs were more strongly assigned to adjacent outcome classes,' which leaves the map incomplete for that outcome class.
• The 'Result-interpretation guardrail' subsection is meta-commentary about how to read the manuscript rather than evidence content, and duplicates material from the Limitations section.
• The Limitations section overstates its case: it claims 'no long-term mortality or hard-outcome randomized trial in non-diabetic, community-dwelling adults' while Rong 2026 is an RCT with a Day 28 FOUR-score endpoint, Rong 2026 measures change over 4 weeks, and Lee 2025 is a cohort with direct clinical endpoints. The statement is directionally true for aging endpoints but not for the corpus as a whole.
• The 75 cross-study disagreements figure is asserted without a reproducible definition (what counts as a disagreement — null vs. positive, different effect sizes, different outcomes?); this makes the heterogeneity claim hard to audit.
• The Search Summary references a retrieval date of 2026-06-22 and a versioned submission directory, but the methods_pack.json and manifest.json are not supplied, so the audit-trail claim is unverifiable in this submission.

Reviewer note

Triage: revise. The submission is structurally an evidence map and avoids collapsing into a single causal or clinical claim, which is the right shape for this article type. However, the map is not faithful to its own source bundle: the stated geroscience/anti-aging framing is sustained by only a small fraction of the 27 admitted sources, which are predominantly about CO poisoning, diabetic foot ulcers, CRAO, burns, radiation enteritis, TBI, fibromyalgia, sleep, and dental microleakage. The outcome-class accounting does not sum to 27 sources or 699 claims, several in-prose citations (Fang 2025, Pindovic 2026, Peng 2025, Alp 2026, Balasubramanian 2021, Ioannidis 2005) are not in the bundle, and the 75-disagreement figure is not operationally defined. The Limitations section is generic and partially misstates the corpus (e.g., asserting no hard-endpoint RCT when Rong 2026 reports a Day 28 FOUR-score change). The Tensions and Gaps section reads as a template rather than a map-specific gap analysis. With bounded edits — reconciling scope to the bundle, adding missing sources or removing uncited ones, fixing the outcome-class math, defining the disagreement count, and rewriting the gaps section against the actual mapped evidence — the manuscript can be brought to an acceptable evidence map. As submitted, source_grounding, synthesis_quality, and claim_evidence_alignment are all below 4, and recommendation must be revise.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis